DuPont Set To Invests $150 Million in Key Markets for Ethylene Copolymers

DuPont today announced that it is investing approximately $150 million to expand and upgrade manufacturing facilities in Europe, the United States and Asia to meet strong demand for its specialty ethylene copolymers in photovoltaics, packaging and automotive markets, as well as for new infrastructure in emerging economies.

"This investment will result in over 200 million pounds of additional capacity, enhanced capability of our current facilities, and reduced energy consumption of our operations," said William F. Weber, global director, DuPont Ethylene Copolymers. "Importantly, it will accelerate DuPont's ability to respond to rapidly growing demand as we serve our customers worldwide."

Newly announced investments include:

-- Added capacity at Dordrecht, the Netherlands, to expand the global
operations network for DuPont(TM) Fusabond(R) modifiers and DuPont(TM)
Bynel(R) adhesive resins and to serve the European market. The new
capacity is expected to be online in 2009.
-- Enhanced capabilities for DuPont(TM) Surlyn(R) ionomer resin and
Vamac(R) ethylene acrylic elastomers from DuPont performance elastomers
and upgrades to improve energy efficiency at DuPont's Sabine operation
in Orange, Tex. These will be operational in 2008 and 2009.
-- Production efficiency investments at the Victoria, Tex., facility for
DuPont(TM) Elvax(R) ethlyene vinyl acetate copolymer (EVA) products.
These will be operational in 2008 and 2009.

As previously announced, DuPont will construct an EVA facility near Beijing, China, with its joint venture partner, Sinopec. The facility, the first EVA manufacturing operation for DuPont in China, will supply a broad range of EVA products, thus strengthening DuPont's position in the world's fastest growing EVA market. The facility will begin operations in 2009.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.